An Exploratory, Open-label Study to Assess the Effect of P-188 NF (Carmeseal-MD) on Safety, on Respiratory and Cardiac Dysfunction and on Upper Limb Strength in Non-ambulatory Patients With Duchenne Muscular Dystrophy (DMD)
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Phrixus Pharmaceuticals
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.
- 15 Jun 2018 Status changed from planning to not yet recruiting.
- 19 Sep 2017 New trial record